Patients diagnosed with non-clear renal cell carcinoma have often been excluded from clinical trials due to the shortage of treatments available, the low incidence of tumours with non-clear histology, and the corresponding diversity of intrinsic molecular features. This approach led to a knowledge gap in finding the optimal treatment for patients diagnosed with non-clear cell renal carcinoma. Cabozantinib, a potent multiple tyrosine kinase receptor inhibitor, has been recently investigated in patients with non-clear cell histologies of renal cell cancer. In this review, we have summarized available data on the use of cabozantinib in non-clear renal cell carcinoma.
Critical reviews in oncology/hematology. 2020 Mar 03 [Epub ahead of print]
Alberto D'Angelo, Stefan Bagby, Giulia Di Pierro, Martina Chirra, Stefania Nobili, Enrico Mini, Donata Villari, Giandomenico Roviello
Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, United Kingdom. Electronic address: ., Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, United Kingdom., School of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy., Department of Oncology, Medical Oncology Unit, University of Siena, Siena, 53100, Italy., Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy., Department of Urology, University of Florence, Florence, Italy.